Yonsei Med J.  2007 Oct;48(5):773-778. 10.3349/ymj.2007.48.5.773.

Macrolide Resistance Trends in beta-Hemolytic Streptococci in a Tertiary Korean Hospital

• Uh Y
• Hwang GY
• Jang IH
• Cho HM
• Noh SM
• Kim HY
• Kwon O
• Yoon KJ

• KMID: 1122613
• DOI: http://doi.org/10.3349/ymj.2007.48.5.773

Abstract

PURPOSE: Erythromycin-resistant beta-hemolytic streptococci (BHS) has recently emerged and quickly spread between and within countries throughout the world. In this study, we evaluate the antimicrobial susceptibility patterns and erythromycin resistance mechanisms of BHS during 2003-2004. MATERIALS AND METHODS: The MICs of seven antimicrobials were determined for 204 clinical isolates of BHS from 2003 to 2004. Resistance mechanisms of erythromycin-resistant BHS were studied by the double disk test as well as by polymerase chain reaction (PCR). RESULTS: Compared with our previous study, resistance among Streptococcus pyogenes isolates to a variety of drugs decreased strikingly: from 25.7% to 4.8% in erythromycin; 15.8% to 0% in clindamycin; and 47.1% to 19.0% in tetracycline. The prevalent phenotypes and genotypes of macrolide-lincosamide-streptograminB (MLSB) resistance in Streptococcus pyogenes isolates have been changed from the constitutive MLSB phenotype carrying erm(B) to the M phenotype with mef(A) gene. In contrast with Streptococcus pyogenes, resistance rates to erythromycin (36.7%), clindamycin (43.1%), and tetracycline (95.4%) in Streptococcus agalactiae isolates did not show decreasing trends. Among the Streptococcus dysgalactiae subsp. equisimilis isolates (Lancefield group C, G), resistance rates to erythromycin, clindamycin, tetracycline and chloramphenicol were observed to be 9.4%, 3.1%, 68.8%, and 9.4%, respectively. CONCLUSION: Continual monitoring of antimicrobial resistance among large-colony-forming BHS is needed to provide the medical community with current data regarding the resistance mechanisms that are most common to their local or regional environments.

Keyword

beta-hemolytic streptococci; antibiotic resistance; macrolides; erythromycin; Streptococcus agalactiae; Streptococcus pyogenes

MeSH Terms

Anti-Bacterial Agents/*pharmacology
Drug Resistance, Multiple, Bacterial
Erythromycin/*pharmacology
Genes, Bacterial
Genotype
Hospitals
Humans
Incidence
Korea
Microbial Sensitivity Tests
Streptococcus/*drug effects/genetics/isolation & purification
Streptococcus agalactiae/drug effects/genetics/isolation & purification
Streptococcus pyogenes/drug effects/genetics/isolation & purification

Reference

1. Ruoff KL, Whiley RA, Beighton D. Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, editors. Streptococcus. Manual of clinical microbiology. 2003. 8th ed. Washington DC: American Society for Microbiology;405–421.

2. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin Infect Dis. 2002. 35:113–125.

3. Schuchat A. Group B streptococcal disease: from trials and tribulations to triumph and trepidation. Clin Infect Dis. 2001. 33:751–756.

4. Biedenbach DJ, Stephen JM, Jones RN. Antimicrobial susceptibility profile among β-haemolytic Streptococcus spp. collected in the SENTRY Antimicrobial Surveillance Program-North America, 2001. Diagn Microbiol Infect Dis. 2003. 46:291–294.

5. Carroll KC, Monroe P, Cohen S, Hoffman M, Hamilton L, Korgenski K, et al. Susceptibility of β-hemolytic streptococci to nine antimicrobial agents among four medical centers in Salt Lake City, Utah, USA. Diagn Microbiol Infect Dis. 1997. 27:123–128.

6. Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR, Mutnick AH. Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis. 2002. 43:157–162.

7. Traub WH, Leonhard B. Comparative susceptibility of clinical group A, B, C, F, and G β-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy. 1997. 43:10–20.

8. Wu JJ, Lin KY, Hsueh PR, Liu JW, Pan HI, Sheu SM. High incidence of erythromycin-resistant streptococci in Taiwan. Antimicrob Agents Chemother. 1997. 41:844–846.

9. Avanzini C, Bosio K, Volpe G, Dotti G, Savoia D. Streptococcus pyogenes collected in Torino (northwest Italy) between 1983 and 1998: survey of macrolide resistance and trend of genotype by RAPD. Microb Drug Resist. 2000. 6:289–295.

10. Kataja J, Huovinen P, Efstratiou A, Pérez-Trallero E, Seppälä H. Macrolide resistance study group. Clonal relationships among isolates of erythromycin-resistant Streptococcus pyogenes of different geographical origin. Eur J Clin Microbiol Infect Dis. 2002. 21:589–595.

11. Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med. 1997. 337:441–446.

12. Chong Y, Lee K. Present situation of antimicrobial resistance in Korea. J Infect Chemother. 2000. 6:189–195.

13. Kim HY, Uh Y. Macrolide resistance in β-hemolytic streptococci: changes after the implementation of the separation of prescribing and dispensing of medications policy in Korea. Yonsei Med J. 2004. 45:591–597.

14. Uh Y, Jang IH, Hwang GY, Lee MK, Yoon KJ, Kim HY. Antimicrobial susceptibility patterns and macrolide resistance genes of β-hemolytic streptococci in Korea. Antimicrob Agents Chemother. 2004. 48:2716–2718.

15. Clinical and Laboratory Standards Institute. CLSI document M100-S16. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. 2006. Wayne (PA): Clinical and Laboratory Standards Institute.

16. Uh Y, Jang IH, Yoon KJ, Kim HY. Serogroup distribution of beta-hemolytic streptococci isolated from a tertiary care hospital at Wonju area during the recent 4 years (1997-2000). Korean J Infect Dis. 2001. 33:173–180.

17. Uh Y, Yong D, Lee K, Kwon O, Yoon KJ. Emergence of erythromycin-resistant Streptococcus agalactiae serotype V is due to clonal spread. Korean J Lab Med. 2005. 25:S564.

18. Ko WC, Lee HC, Wang LR, Lee CT, Liu AJ, Wu JJ. Serotyping and antimicrobial susceptibility of group B Streptococcus over an eight-year period in southern Taiwan. Eur J Clin Microbiol Infect Dis. 2001. 20:334–339.

19. Malbruny B, Werno AM, Anderson TP, Murdoch DR, Leclercq R. A new phenotype of resistance to lincosamide and streptogramin A-type antibiotics in Streptococcus agalactiae in New Zealand. J Antimicrob Chemother. 2004. 54:1040–1044.

20. Woo PC, Fung AM, Lau SK, Wong SS, Yuen KY. Group G beta-hemolytic streptococcal bacteremia characterized by 16S ribosomal RNA gene sequencing. J Clin Microbiol. 2001. 39:3147–3155.

21. Zaoutis T, Schneider B, Steele Moore L, Klein JD. Antibiotic susceptibilities of group C and group G streptococci isolated from patients with invasive infections: evidence of vancomycin tolerance among group G serotypes. J Clin Microbiol. 1999. 37:3380–3383.

22. Hashikawa S, Iinuma Y, Furushita M, Ohkura T, Nada T, Torii K, et al. Characterization of group C and G streptococcal strains that cause streptococcal toxic shock syndrome. J Clin Microbiol. 2004. 42:186–192.